Indication
Prophylaxis of influenza in individuals 60 years of age and over, especially in those who run an increased risk of associated complications.The use of IDflu should be based on official recommendations.
Loading your page…
Loading your page…
Influenza, Human;Immunization
Marketing Authorisation Holder: Sanofi Pasteur S.A.
EMA Authorisation: 24/02/2009
INN: influenza vaccine (split virion, inactivated)
AI Drug & Interaction Analysis
Free account required
Ask Osler about IDflu: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.